Physician Assistant Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Laura Hubbs

Pain Medicine Norfolk, VA Physician Assistant

NPI 1417428715 CMS profile 10418408

6275 E Virginia Beach Blvd Ste 303, Norfolk, VA 23502

Open in the dashboard

General payments

$3,035

156 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Hubbs of Norfolk, VA is reported in the CMS Open Payments database as having received $3,035 across 156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,607 80
2024 General $1,427 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Hubbs
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Laura Hubbs were reported at $1,607. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Laura Hubbs Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $0 $335 $103–$1,149 $149
2023 $0 $376 $114–$1,228 $160
2024 $1,427 $387 $115–$1,173 $164
2025 $1,607 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AbbVie, Inc. $708 39 payments
  2. Lundbeck LLC $671 28 payments
  3. Pfizer Inc. $525 35 payments
  4. Collegium Pharmaceutical, Inc. $433 22 payments
  5. Vertex Pharmaceuticals Incorporated $129 5 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $113 6 payments
  7. Lilly USA, LLC $102 5 payments
  8. Axsome Therapeutics, Inc. $77 3 payments
  9. Averitas Pharma Inc. $58 3 payments
  10. TerSera Therapeutics LLC $55 2 payments
  11. Other $164 8 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $3,035 156 payments
Products named General payments · program years 2024–2025
  1. VYEPTI $671 28 payments
  2. QULIPTA $527 30 payments
  3. NURTEC ODT $525 35 payments
  4. ZAVZPRET $525 35 payments
  5. UBRELVY $472 27 payments
  6. BELBUCA $291 16 payments
  7. BOTOX $199 10 payments
  8. XTAMPZA $142 6 payments
  9. RELISTOR $113 6 payments
  10. EMGALITY $102 5 payments
  11. Other $505 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,710

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$162,665

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

25%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 33 $56,158
Nurtec Odt Rimegepant Sulfate Brand 20 $34,389
Oxycodone Hcl Generic 376 $16,064
Fentanyl Generic 71 $14,002
Xtampza Er Oxycodone Myristate Brand 11 $10,475
Morphine Sulfate Er Morphine Sulfate Brand 128 $5,728
Hydromorphone Hcl Generic 87 $3,057
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 72 $2,477
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 73 $2,391
Morphine Sulfate Generic 35 $2,077

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $304
$304 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $144
$144 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $142
$142 11 —
NURTEC ODT
  • PFIZER INC. $127
$127 20 —
ZAVZPRET
  • PFIZER INC. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record